Product Description
Salbutamol, the most commonly used bronchodilator, is a chiral drug with R (levosalbutamol) and S-isomers (also known as enantiomer). The commonly used formulation is a racemic mixture that contains equal amounts of both R and S isomers. Levosalbutamol is the therapeutically active isomer and has all the beta 2 agonist activity. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/17337829/)
Mechanisms of Action: ADRB2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | Colombia | Dominican Republic | Ecuador | India | Peru | Russia | Turkey | United States
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Turkey
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Chronic Obstructive Pulmonary Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NEU-01.22 | P3 |
Active, not recruiting |
Chronic Obstructive Pulmonary Disease |
2024-06-01 |
92% |
| NEU-01.22 | P3 |
Active, not recruiting |
Chronic Obstructive Pulmonary Disease |
2024-06-01 |
92% |
| NEU-02.22 | P3 |
Recruiting |
Chronic Obstructive Pulmonary Disease |
2024-02-06 |
92% |
| NEU-02.22 | P3 |
Recruiting |
Chronic Obstructive Pulmonary Disease |
2024-02-06 |
92% |